Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMonoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
Cochrane Reviews, 10/09/09
Caslake R R et al. – Currently, there are several different treatments available for people with newly diagnosed Parkinson's including levodopa which is converted into dopamine in the brain, dopamine agonists which mimic the action of dopamine, and monoamine oxidase B (MAO–B) inhibitors (selegiline or rasagiline) which reduce the breakdown of dopamine in the brain. Each of these types of drugs has theoretical advantages and disadvantages. For example, although a very good treatment, levodopa can cause involuntary movements (dyskinesia), painful cramps (dystonia) and a shortened response to each dose (motor fluctuations) after a while, whilst MAO–B inhibitors and dopamine agonists may reduce the risk of these complications but are not so good at improving the symptoms of Parkinson's...Unfortunately the authors only identified two trials (593 patients) so there was only limited evidence. MAO–B inhibitors are one option for the early treatment of PD although they have weaker symptomatic effects than levodopa and dopamine agonists. They may reduce the rate of motor fluctuations compared with initial levodopa therapy and may have fewer significant adverse effects than the older agonists but data are too few to provide reliable conclusions.
Related Articles
Widely Used Cholesterol-lowering Drug May Prevent Progression Of Parkinsons Disease
ScienceDaily, 11/10/09
Relevance Score: 82%
What is Parkinsons Disease?
Internet Source, 11/09/09
Relevance Score: 81%
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Relevance Score: 81%
Widely used cholesterol-lowering drug may prevent progression
EurekAlert, 10/30/09
Relevance Score: 81%
The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Therapeutics and Clinical Risk Management, 10/07/09
Relevance Score: 81%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/11/09
Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/11/09
Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor